U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07702981) titled 'Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome' on July 02.
Brief Summary: Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
Study Start Date: June 01, 2023
Study Type: OBSERVATIONAL
Condition:
Membranous Nephropathy
Minimal Change Disease (MCD)
Focal Segmental Glomerulosclerosis (FSGS)
Intervention:
DRUG: Rituximab (MABTHERA(R) or RITUXAN(R)).
Patients with primary MN treated with Rituximab
DRUG: Corticosteroids (CS)
Patients with MCD treated with Corticoste...